PEPTIDE SCIENCE 101 · RESEARCH PROTOCOLS & STACKS
Conventional wisdom frames cognitive decline, epigenetic aging, and neurodegeneration as separate problems requiring separate interventions. The preclinical literature from the St. Petersburg Institute of Bioregulation and Gerontology — and increasingly from independent Western laboratories — suggests a more integrated picture: a cluster of short-chain bioregulators originally developed by Vladimir Khavinson and colleagues may address these processes through complementary, non-overlapping mechanisms that converge on the aging brain.
The Khavinson Triple is a curated research stack comprising three compounds: Epithalon (tetrapeptide AEDG, Ala-Glu-Asp-Gly), Pinealon (tripeptide EDR, Glu-Asp-Arg), and Semax (heptapeptide ACTH 4–10 analogue, Met-Glu-His-Phe-Pro-Gly-Pro). Each compound targets a distinct axis: telomere biology and epigenetic remodelling (Epithalon), neuroprotective gene expression and dendritic structural integrity (Pinealon), and BDNF-driven neurotrophin signalling alongside HPA-axis regulation (Semax).
What makes this combination worth examining is the mechanistic logic. These three signalling molecules do not appear to compete at the primary pathway level. Epithalon’s primary documented targets — hTERT mRNA, chromatin condensation state, and melatonin synthesis — are functionally upstream of the acute neurological targets where Pinealon and Semax operate. Pinealon’s proposed MAPK/ERK suppression of proapoptotic proteins and Semax’s BDNF/trkB upregulation represent two distinct arms of neuroprotection. That theoretical separation is worth examining carefully — and so are its limits.
This post compiles the available preclinical evidence for all three compounds, maps their known mechanisms, and is direct about where the data runs out.
The three compounds in this stack have been studied across a range of experimental models spanning invertebrates, rodents, bovine oocytes, and human cell lines. No study has examined all three compounds administered together. The stack rationale is constructed entirely from individual compound data; no synergy, interaction, or combination pharmacodynamics data exists in the peer-reviewed literature.
Epithalon (AEDG) has the deepest research footprint of the three. Khavinson VK et al. (2000) first demonstrated lifespan extension in Drosophila melanogaster Canton-S wild strain, where Epitalon supplemented during developmental stages at concentrations of 0.001×10⁻⁶ to 5×10⁻⁶ wt.% of culture medium increased adult lifespan by 11–16% — at concentrations 16,000 to 80,000,000-fold lower than melatonin concentrations required for comparable effects (Khavinson VK et al., 2000, PMID: 11087911). In mammalian models, Anisimov VN et al. (2001) administered monthly subcutaneous injections of 0.1 µg/animal to female CBA mice from age 6 months until death (n=50 per group), observing a 5.3% increase in mean survival (p<0.05) and up to 10 additional months of maximum lifespan vs. saline controls (PMID: 11163623). More recently, Al-Dulaimi S et al. (2025) moved into human cell line models, quantifying hTERT mRNA expression, telomerase enzyme activity, and alternative lengthening of telomeres (ALT) in parallel across normal epithelial cells, fibroblasts, and breast cancer cell lines (PMID: 40908429).
Pinealon (EDR) has a comparatively sparse PubMed footprint under that compound name, with the majority of mechanistic work published under the EDR designation. Khavinson V et al. (2020) synthesised the molecular biology in a comprehensive review examining in vitro neuronal culture data from Alzheimer’s and Huntington’s disease models (PMID: 33396470). Kraskovskaya N et al. (2024) used a human induced-neuron model — transdifferentiating fibroblasts from elderly donors — to examine EDR’s effects on dendritic architecture and oxidative DNA damage (PMID: 39518916).
Semax has the most substantial independent Western research base. Dolotov OV et al. (2006) characterised the BDNF/trkB mechanism using intranasal dosing in rat hippocampal slice and in vivo models (PMID: 16996037). Filippenkov IB et al. (2024) applied full RNA-Seq to a rat transient middle cerebral artery occlusion (tMCAO) ischemic stroke model 24 hours post-injury (PMID: 39767736). Inozemtseva LS et al. (2024) examined HPA-axis effects in a male Sprague-Dawley rat chronic unpredictable stress (CUS) model using daily intraperitoneal dosing at 60 nmol/kg body weight (PMID: 39442746).
The 2025 Al-Dulaimi study represents the most mechanistically precise Epithalon data to date. Dose-dependent telomere length extension was confirmed in normal human epithelial cells and fibroblasts via upregulation of hTERT mRNA expression and telomerase enzyme activity (Al-Dulaimi S et al., 2025, PMID: 40908429). Notably, in breast cancer cell lines (21NT, BT474), telomere lengthening occurred through ALT activation rather than telomerase — a pathway-selective difference that suggests the compound interacts with cellular context, not just a single universal target.
At the epigenetic level, Lezhava T et al. (2023) demonstrated that Epithalon induced selective decondensation of both eu- and heterochromatin regions in lymphocyte cultures from donors aged 75–88 years, activating ribosomal gene synthesis from acrocentric chromosome satellite stalks (PMID: 37042594). Critically, Epithalon did not deheterochromatinise pericentromeric structural heterochromatin — indicating targeted, not global, epigenetic remodelling. This selectivity is mechanistically significant: nonspecific chromatin opening would carry genomic instability risk. The compound appears to reverse age-associated gene silencing in a constrained, region-specific manner.
Antioxidant activity has been documented across multiple independent cell models. In ARPE-19 human retinal pigment epithelial cells under high-glucose conditions, Gatta M et al. (2025) showed Epithalon reduced intracellular ROS, restored antioxidant gene expression, and inhibited epithelial-mesenchymal transition and fibrosis-related gene upregulation (PMID: 40493162). In a mouse oocyte aging model, 0.1 mM Epithalon significantly reduced ROS at 6h, 12h, and 24h post-ovulation, decreased spindle defect frequency at 12h and 24h, and preserved mitochondrial membrane potential and DNA copy number (Yue X et al., 2022, PMID: 35413689).
The comprehensive 2025 review by Araj SK et al. identifies additional confirmed mechanisms: direct stimulation of melatonin synthesis in pineal gland cells, alteration of IL-2 mRNA levels, modulation of murine thymocyte mitogenic activity, and enhancement of acetylcholinesterase and butyrylcholinesterase enzyme activities — with antioxidant potency in Drosophila models described as markedly higher than melatonin at equivalent doses (PMID: 40141333).
Pinealon’s proposed mechanism centres on intracellular entry followed by binding to histone proteins and/or RNA, with downstream modulation of the MAPK/ERK signalling pathway, suppression of proapoptotic proteins caspase-3 and p53, and upregulation of antioxidant enzymes SOD2 and GPX1 (Khavinson V et al., 2020, PMID: 33396470). The review also identifies modulation of transcription factors PPARA and PPARG and influence on serotonin and calmodulin signalling pathways as part of the proposed anti-neurodegenerative mechanism.
In the 2024 Kraskovskaya study — using induced neurons transdifferentiated from aged human fibroblasts — EDR (Pinealon) promoted dendritic arborisation, increasing both the number of primary dendritic processes and total dendritic length (PMID: 39518916). Specifically, EDR reduced oxidative DNA damage in neurons from elderly donors — an effect not replicated to the same degree by co-tested AEDG (Epithalon) or KED in this particular model. The tripeptides did not affect mitochondrial or lysosomal activity or p16 protein levels, indicating that Pinealon’s protective activity is partial in scope and should not be overstated.
The 2020 Khavinson review additionally notes that EDR prevented elimination of dendritic spines in neuronal cultures from Alzheimer’s and Huntington’s disease mouse models — though the review’s synthesis of limited human data reporting improved memory metrics in elderly subjects is explicitly described as preliminary and not characterised as controlled trial evidence.
Semax’s best-characterised mechanism is the upregulation of the hippocampal BDNF/trkB neurotrophin axis. Dolotov OV et al. (2006) established that a single intranasal application at 50 µg/kg produced: a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in trkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in trkB mRNA in rat hippocampus (PMID: 16996037). These molecular changes correlated with increased conditioned avoidance reactions, linking the neurotrophin upregulation to a measurable behavioural outcome.
The 2024 Filippenkov RNA-Seq study adds a transcriptomic dimension to this picture. In rats subjected to tMCAO, Semax administration compensated for the disrupted expression of 1,171 out of 3,774 ischemia-disrupted genes (fold change >1.5, Padj <0.05) at the 24-hour timepoint, with enrichment specifically in immune-suppressive, neurosignalling, neurogenesis, angiogenesis, protein kinase, and growth factor gene sets (PMID: 39767736). This transcriptomic breadth suggests Semax’s neuroprotective profile is not reducible to a single receptor interaction.
On the HPA axis: at 60 nmol/kg/day intraperitoneal in the CUS model, Semax reversed anhedonia (sucrose preference test), attenuated body weight suppression, prevented adrenal hypertrophy, and restored hippocampal BDNF levels toward control values (Inozemtseva LS et al., 2024, PMID: 39442746). The authors frame this as melanocortin receptor-mediated modulation of BDNF signalling, noting that effects were observed on anhedonia and HPA-axis dysregulation but not on forced-swim immobility — suggesting pathway specificity rather than global antidepressant activity.
A 2025 study introduced a novel Semax mechanism: µ-opioid receptor (Oprm1) targeting in a murine spinal cord injury model (T9-T10, female C57BL/6), with downstream regulation of USP18 deubiquitinase and FTO deubiquitination proposed as the pathway for reduced lysosomal membrane permeabilisation and pyroptosis (Liu R et al., 2025, PMID: 40692165). In transgenic Alzheimer’s mice (APPswe/PS1dE9/Blg), Semax improved performance across open field, novel object recognition, and Barnes maze tests and reduced cortical and hippocampal amyloid plaque burden (Radchenko AI et al., 2025, PMID: 41479572).
Table 1: Epithalon (AEDG) — Key Preclinical Findings
| Study Type | Model | Key Outcome | Citation |
|---|---|---|---|
| In vitro (human cell lines) | Normal epithelial cells, fibroblasts | Dose-dependent telomere length extension via hTERT mRNA upregulation and telomerase activation | Al-Dulaimi S et al., 2025, PMID: 40908429 |
| In vitro (human lymphocytes, aged donors 75–88y) | Lymphocyte cultures | Selective chromatin decondensation; ribosomal gene reactivation; reversal of age-related gene silencing | Lezhava T et al., 2023, PMID: 37042594 |
| In vitro (mouse oocyte aging) | Mouse oocytes at 6h, 12h, 24h post-ovulation | 0.1 mM: reduced ROS, reduced spindle defects, preserved mitochondrial membrane potential and mtDNA copy number | Yue X et al., 2022, PMID: 35413689 |
| In vivo (mouse lifespan) | Female CBA mice, n=50, 0.1 µg/animal monthly s.c. | +5.3% mean survival (p<0.05); +up to 10 months maximum lifespan; reduced spontaneous tumour incidence | Anisimov VN et al., 2001, PMID: 11163623 |
| In vivo (Drosophila lifespan) | Canton-S wild strain, developmental dosing | +11–16% adult lifespan; effective at 16,000–80,000,000× lower concentration than melatonin | Khavinson VK et al., 2000, PMID: 11087911 |
| Narrative review (25+ years) | In vitro, in vivo, in silico synthesis | Confirmed mechanisms: melatonin synthesis stimulation, IL-2 mRNA modulation, thymocyte activity, AChE/BuChE enhancement | Araj SK et al., 2025, PMID: 40141333 |
Table 2: Pinealon (EDR) and Semax — Key Preclinical Findings
| Compound | Study Type | Model | Key Outcome | Citation |
|---|---|---|---|---|
| Pinealon (EDR) | Molecular review + in vitro | Alzheimer’s/Huntington’s neuronal cultures; rat cerebellar neurons | MAPK/ERK modulation; caspase-3/p53 suppression; SOD2/GPX1 upregulation; dendritic spine preservation | Khavinson V et al., 2020, PMID: 33396470 |
| Pinealon (EDR) | In vitro (human induced neurons from aged donors) | Fibroblast-derived neurons, elderly donors | Increased dendritic arbourisation (primary processes + total length); reduced oxidative DNA damage | Kraskovskaya N et al., 2024, PMID: 39518916 |
| Semax | In vivo (rat, intranasal) | Rat hippocampus, 50 µg/kg single dose | +1.4× BDNF protein; +1.6× trkB phosphorylation; +3× BDNF mRNA (exon III); improved conditioned avoidance | Dolotov OV et al., 2006, PMID: 16996037 |
| Semax | In vivo (rat, tMCAO stroke model) | RNA-Seq, 24h post-stroke | Compensated 1,171/3,774 ischemia-disrupted genes; enriched: immune suppression, neurogenesis, angiogenesis | Filippenkov IB et al., 2024, PMID: 39767736 |
| Semax | In vivo (rat, CUS depression model) | Male Sprague-Dawley, 60 nmol/kg/day i.p. | Reversed anhedonia; prevented adrenal hypertrophy; restored hippocampal BDNF | Inozemtseva LS et al., 2024, PMID: 39442746 |
| Semax | In vivo (transgenic mouse, Alzheimer’s model) | APPswe/PS1dE9/Blg mice | Improved 3 cognitive batteries; reduced cortical and hippocampal amyloid plaque burden | Radchenko AI et al., 2025, PMID: 41479572 |
The theoretical basis for combining these three bioregulators rests on the non-overlap of their primary documented targets. Epithalon operates primarily at the chromatin and telomere level — upstream, slow-timescale processes that reflect cumulative genomic aging. Pinealon operates at the level of gene expression regulation and dendritic structural maintenance in neurons — a mid-timescale structural neuroprotective role. Semax operates at the fastest timescale of the three, acutely upregulating BDNF/trkB signalling, modulating HPA-axis tone, and producing transcriptomic compensation within 24 hours of neural stress.
This is mechanistic complementarity in theory. It is not proven synergy. The combination has never been studied in any peer-reviewed preclinical model.
For Epithalon, the evidence base is the most developed: multiple independent laboratories across the UK (Brunel University London), Italy (Chieti-Pescara University), and China have now confirmed telomerase activation and antioxidant mechanisms in human cell models, adding independent replication to the foundational Russian institutional work. The Drosophila and CBA mouse lifespan data remain unique in showing survival endpoints rather than surrogate biomarkers, but they come with the extrapolation caveats this work always carries.
For Semax, the evidence for BDNF/trkB upregulation is well-replicated across multiple independent laboratories and animal models. The 2024 RNA-Seq study is particularly valuable: transcriptomic breadth at the gene-set level is a more granular mechanistic anchor than single-pathway claims.
For Pinealon, honest assessment requires acknowledging a genuine evidence gap. The PubMed footprint under “Pinealon” is thin. The mechanistic work under the EDR designation is scientifically credible but originates almost entirely from the Khavinson group — the same investigators who developed the compound. The 2024 Kraskovskaya study provides meaningful independent validation for the dendritic arborisation finding, but the evidence base for Pinealon is proportionally thinner than for its two stack partners.
1. No combination data exists. No peer-reviewed study has administered Epithalon, Pinealon, and Semax together in any model — animal or human. All stack-level mechanistic claims are theoretical constructs assembled from individual compound data. No additive, synergistic, or antagonistic interactions have been characterised. Any claim about “how the stack works” is extrapolation, not experimental finding.
2. Predominantly preclinical and in vitro evidence. Human randomised controlled trial (RCT) data is absent for Epithalon and Pinealon. Semax has limited Russian-language clinical exposure data in ischemic stroke that has not been replicated in large Western multi-centre RCTs. The CBA mouse lifespan study (n=50, Anisimov et al., 2001, PMID: 11163623), while among the strongest survival endpoint studies available, used sample sizes that are insufficient to establish dose-response relationships or mechanistic precision by contemporary statistical standards. In vitro models — ARPE-19 retinal cells, THP-1 monocytes, oocyte culture systems — do not capture blood-brain barrier penetration, systemic first-pass metabolism, or the competing neuropathological cascades present in living organisms.
3. Publication concentration and potential conflict of interest. The majority of Pinealon/EDR and historical Epithalon literature originates from the St. Petersburg Institute of Bioregulation and Gerontology — the institution that developed these compounds under Khavinson’s programme. Independent replication has improved in recent years (2024–2025 publications from Western and Chinese institutions), but the historical literature carries investigator conflict-of-interest risk that cannot be dismissed. The recent independent replications are encouraging but do not yet constitute a deep, diverse citation base.
4. Oral bioavailability is not established. No validated pharmacokinetic or pharmacodynamic data exists to translate effective doses from Drosophila, mouse, rat, or cell culture models to any human-relevant dosing context. Oral bioavailability data for intact tetrapeptide and tripeptide absorption is not established in peer-reviewed form for any of the three compounds. Effective in vitro concentrations (e.g., 0.1 mM for Epithalon in oocyte models; 50 µg/kg intranasal for Semax in rats) cannot be linearly extrapolated to human administration routes or systemic exposures.
5. Longevity endpoint timing and adult-onset dosing. The lifespan extension findings in Drosophila and CBA mice used dosing initiated during developmental stages or early adulthood. Whether equivalent geroprotective effects occur with adult-onset dosing — the context most relevant to self-optimisers — has not been directly examined.
6. Model-to-mechanism translation gaps. Semax’s µ-opioid receptor mechanism (Liu et al., 2025, PMID: 40692165) was identified in a spinal cord injury model and is mechanistically distinct from its BDNF/melanocortin pathway. The existence of multiple proposed Semax mechanisms is scientifically interesting but also indicates incomplete mechanistic characterisation. What the dominant pathway is in a healthy, non-injured organism remains an open question.
The Khavinson Triple — Epithalon, Pinealon, and Semax — represents one of the more mechanistically coherent compound combinations in the bioregulator research space. Each signalling molecule targets a distinct aspect of neurological and cellular aging: upstream epigenetic and telomere maintenance (Epithalon), neuroprotective gene regulation and dendritic structural preservation (Pinealon), and acute BDNF-driven neurotrophin signalling with HPA-axis modulation (Semax). The theoretical rationale for non-overlap at the primary mechanism level is sound based on current data.
The evidentiary picture is strongest for Epithalon and Semax, where multiple independent laboratories have replicated core mechanisms in diverse models. Pinealon’s data, while biologically credible, is predominantly from a single research group and requires substantially more independent validation before mechanistic confidence approaches that of its stack partners.
For researchers examining this combination, the salient protocol context is this: the compounds have been studied individually across a range of preclinical models with consistent mechanistic signals. The combination remains unstudied. The appropriate research posture is to treat each compound’s evidence base separately, maintain realistic expectations about what preclinical biomarker data implies for human outcomes, and track the emerging independent replication literature — particularly for Pinealon, where the evidence gap is most pronounced.
The Khavinson Triple stack is available through our research compound catalogue. For related compound profiles, see our longevity compound category and cognitive compound category. Additional mechanistic overviews are available in our research notes.
Al-Dulaimi S et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. PMID: 40908429
Araj SK et al. (2025). Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. PMID: 40141333
Gatta M et al. (2025). The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Reviews and Reports. PMID: 40493162
Yue X et al. (2022). Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging (Albany NY). PMID: 35413689
Avolio F et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences. PMID: 35408963
Lezhava T et al. (2023). Epigenetic Modification Under the Influence of Peptide Bioregulators on the ‘Old’ Chromatin. Georgian Medical News. PMID: 37042594
Khavinson V et al. (2020). EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. PMID: 33396470
Kraskovskaya N et al. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. PMID: 39518916
Dolotov OV et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. PMID: 16996037
Filippenkov IB et al. (2024). ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. PMID: 39767736
Inozemtseva LS et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology. PMID: 39442746
Liu R et al. (2025). Semax peptide targets the µ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology. PMID: 40692165
Radchenko AI et al. (2025). The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease. Acta Naturae. PMID: 41479572
Anisimov VN et al. (2001). Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development. PMID: 11163623
Khavinson VK et al. (2000). Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. PMID: 11087911
This post was prepared by the biohacker.team research writing team, drawing on primary PubMed-indexed literature retrieved and verified against original abstracts and full-text sources. All compounds referenced in our catalogue — including Epithalon, Pinealon, and Semax — are tested for identity, purity, and sterility by independent third-party laboratories. Certificates of Analysis (COA) with HPLC purity data (≥98% target purity) are available on request and linked from individual product pages. We source from GMP-compliant manufacturers and do not publish product pages without current COA documentation. Our research notes are available at biohacker.team/research/, and sourcing transparency is detailed at biohacker.team/about/.
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.